- Home
- URGN vs NBR Comparison
URGN vs NBR Comparison
Compare URGN & NBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- NBR
- Stock Information
- Founded
- URGN 2004
- NBR 1952
- Country
- URGN United States
- NBR Bermuda
- Employees
- URGN N/A
- NBR N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- NBR Oil & Gas Production
- Sector
- URGN Health Care
- NBR Energy
- Exchange
- URGN Nasdaq
- NBR Nasdaq
- Market Cap
- URGN 463.2M
- NBR 417.7M
- IPO Year
- URGN 2017
- NBR N/A
- Fundamental
- Price
- URGN $4.24
- NBR $25.78
- Analyst Decision
- URGN Strong Buy
- NBR Hold
- Analyst Count
- URGN 8
- NBR 8
- Target Price
- URGN $27.92
- NBR $44.13
- AVG Volume (30 Days)
- URGN 2.4M
- NBR 459.7K
- Earning Date
- URGN 05-12-2025
- NBR 07-22-2025
- Dividend Yield
- URGN N/A
- NBR N/A
- EPS Growth
- URGN N/A
- NBR N/A
- EPS
- URGN N/A
- NBR N/A
- Revenue
- URGN $91,871,000.00
- NBR $2,932,608,000.00
- Revenue This Year
- URGN $35.06
- NBR $14.94
- Revenue Next Year
- URGN $112.94
- NBR $6.41
- P/E Ratio
- URGN N/A
- NBR N/A
- Revenue Growth
- URGN 8.98
- NBR N/A
- 52 Week Low
- URGN $3.42
- NBR $23.27
- 52 Week High
- URGN $20.70
- NBR $105.96
- Technical
- Relative Strength Index (RSI)
- URGN 27.72
- NBR 41.55
- Support Level
- URGN $3.71
- NBR $25.07
- Resistance Level
- URGN $4.25
- NBR $27.20
- Average True Range (ATR)
- URGN 0.91
- NBR 1.70
- MACD
- URGN -0.45
- NBR 0.00
- Stochastic Oscillator
- URGN 9.87
- NBR 26.23
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About NBR Nabors Industries Ltd.
Nabors Industries Ltd owns and operates land-based drilling rig fleets and is a provider of offshore platform rigs in the United States and international markets. It also provides performance tools, directional drilling services, tubular running services, and technologies. The company has four reportable segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. The key revenue of the company is generated from International Drilling.